Titelbild

Pipeline

Topas pursues a number of proprietary drug development programs which cover the areas of autoimmune diseases, allergies and anti-drug-antibodies (ADA). At the same time Topas remains open for collaborative programs in these areas with interested parties.

Indication Discovery in-vivo POC pre-IND Phase I
Multiple Sclerosis
Orphan Disease
Type 1 Diabetes
Celiac Disease
ADA-1